Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial
Salehidoost R, Taghipour Boroujeni G, Feizi A, Aminorroaya A, Amini M
Scientific reports · 19 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2022-10-28 · Sci Rep · vol. 12 · issue 1 · p. 18209
- Publisher
- Nature Portfolio
- Cited
- 20 citations · more than 85% of similar papers · 1.8× the field average
- References
- 45 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Plant Micronutrient Interactions and Effects
- Keywords
- Prediabetes, Medicine, Internal medicine, Placebo, Endocrinology, Insulin resistance, Triglyceride, Lipid profile, Blood pressure, Uric acid, Insulin, Cholesterol, Anthropometry, Body mass index, Randomized controlled trial, Type 2 diabetes, Gastroenterology, Diabetes mellitus
- MeSH
- humans, cardiovascular diseases, prediabetic state, insulin resistance, magnesium, uric acid, blood glucose, c-reactive protein, double-blind method, dietary supplements, cholesterol, hdl, biomarkers
5 authors
From IR
- Rezvan SalehidoostIsfahan University of Medical Sciences
- Golshan Taghipour BoroujeniShahrekord University of Medical Sciences
- Awat FeiziIsfahan University of Medical Sciences
- Ashraf Aminorroaya · correspondingIsfahan University of Medical Sciences
- Masoud Amini · correspondingIsfahan University of Medical Sciences
Abstract
To evaluate the effect of magnesium supplementation on insulin resistance and cardiovascular markers in people with prediabetes. A 12 week double-blind placebo-controlled randomized clinical trial was conducted at Isfahan Endocrine and Metabolism Research Center, Iran, on people with prediabetes (n = 86) to compare the effects of magnesium oxide 250 mg/day versus a placebo on anthropometric indices, blood pressure, fasting glucose, insulin, HOMA-IR index, C-reactive protein, uric acid and lipid profile. Both groups had similar distributions of anthropometric and biochemical variables at baseline. Those who received magnesium supplementation had significantly higher levels of HDL-cholesterol compared to the placebo group at the end of the study (49.7 ± 10.9 vs 43.6 ± 7.2 mg/dL, P = 0.003). The mean changes of HOMA-IR index, total cholesterol, LDL-cholesterol, triglyceride, uric acid and C-reactive protein levels as well as anthropometric indices and blood pressure in supplemented and placebo groups did not differ significantly. Magnesium supplementation increased HDL-cholesterol levels in people with prediabetes. However, other cardiometabolic markers were not improved by magnesium supplementation at the above dosage and duration.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.